Global Active Pharmaceutical Ingredient Market Poised to Grow at
4.5% CAGR Over 2025
An active pharmaceutical ingredient is used in a finished pharmaceutical product (FPP), intended to
carry certain pharmacological actions or otherwise have a direct effect in the diagnosis, cure,
treatment, mitigation or prevention of various diseases, or in some cases in restoring, correcting or
modifying human physiological functions. Sales of pharmaceutical ingredient are on the rise due to
a substantial increase in high-potency API (HPAPI) and peptide API manufacturing. A new study
conducted by Persistence Market Research reveals that the US$ 151.9 Bn global active
pharmaceutical ingredient market will grow to US$ 158.3 Bn by 2017 end, reflecting a Y-o-Y
growth rate of 4.2%. This market is estimated to further increase to US$ 225.2 Bn, expanding at a
CAGR of 4.5% over the forecast period (2016 – 2025)
PMR in its report, titled “Active Pharmaceutical Ingredient Market – Global Industry Analysis and
Forecast, 2016 – 2025” has cited some of the key factors prompting the global sales of API, which
include:




Higher emphases on the development of novel therapeutics that contain high-potency active
pharmaceutical ingredients (HPAPIs).
Ramped-up investments from large-scale API manufacturers and contract manufacturers in
production of high potency API.
The lower cost of labor cost and abundance of raw materials continue to facilitate the
growth of API market in the Asia region.
Faster approvals of API based peptide and diabetes management drugs. Over the recent past,
a range of peptide drugs has been approved treatment of type 2 Diabetes Mellitus including
Albiglutide (GSK), Dulaglutide (Eli Lilly), Exenatide (Amylin Pharmaceuticals) and
Glucagon (Xeris Pharmaceuticals).
Download Report Table of Content, Figures, and Tables @
http://www.persistencemarketresearch.com/market-research/active-pharmaceutical-ingredientmarket/toc
According to the report, small molecule API type segment holds promising investment
opportunities for market participants on account of the numerous off-patent events incurred in the
last five years coupled with a strong penetration of small scale manufacturers in Asia. On the basis
region, APAC’s API market was valued at US$ 61.4 Bn in 2016 and is projected to witness the
highest CAGR of 5.1 % during the forecast period to reach a valuation of US$ 95.6 Bn. This is
primarily owing to the leadership of China and India in SMEs as well as their strong distribution
network in overseas markets especially in US, South Africa, and Europe. Asian pharmaceuticals
CMOs are competing on the basis of cost and timeline for API manufacturing and are attracting
U.S.-based pharmaceuticals companies that are willing to outsource manufacturing requirements.
Meanwhile, Europe is projected to be the second fastest growing market for API and is expected to
reach US$ 42.5 Bn by 2025-end. Manufacturers in Europe are prioritizing high-quality standards,
advanced manufacturing installations, and high purity of intermediates (API).
A sample of this report is available upon request @
http://www.persistencemarketresearch.com/samples/11260
Johnson Matthey, Siegfried, Almac, PolyPeptide Laboratories, AmbioPharm, Inc., Corden Pharma,
Pepscan, BCN peptide, Provence Technologies Groups, SennChemicals AG, Avecia
OligoMedicines, Santaris Pharma - acquired by Roche in 2014, ST Pharm Oligo Center, Cepia
Sanofi, Biospring, Pfizer CenterSource, Symbiotec Pharma Lab Pvt. Ltd., Gadea Grupo
Farmacéutico, STEROID S.p.A., Dolder AG, Dalton Pharma Services, FarmaBios Spa, Dextra
Laboratories Limited, GlycoSyn, Inalco Pharma, Sussex Research, Pfanstiehl, Inc., Noramco, Inc.,
Johnson Matthey, Siegfried, Rhodes Technologies, Ash Stevens, Fermion (public),
FARMHISPANIA GROUP, Olon SpA, Lonza Group are some of the leading companies operating
in the global active pharmaceutical ingredient market. Currently, many of the pharmaceutical
companies are focused on outsourcing of API manufacturing to avoid large capital investments in
setting up of API manufacturing facilities. This has accelerated the demand for CMOs in API
manufacturing industry, which is dominated by small to medium manufacturers.
Browse Complete Report @ http://www.persistencemarketresearch.com/market-research/activepharmaceutical-ingredient-market.asp
About Us:
Persistence Market Research (PMR) is a third-platform research firm. Our research
model is a unique collaboration of data analytics and market research methodology to
help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a
multi-disciplinary approach. At PMR, we unite various data streams from multidimensional sources. By deploying real-time data collection, big data, and customer
experience analytics, we deliver business intelligence for organizations of all sizes.
Our offerings include pre-built reports that address every major sale, customized
solutions to cater to client-specific needs, and consulting services to offer more value
addition. Our next-generation research approach for exploring emerging technologies
has allowed us to solve the most complex problems of clients. We do not follow a
reactive approach, but a pro-active one. Expert analysts at PMR keep a tab on nextgeneration technologies in their R&D phase and provide the latest insights into these
technologies when they are being commercialized. Our ground-breaking approach
allows us to deliver market solutions before the technologies reach the market.
Our client success stories feature a range of clients from Fortune 500 companies to
fast-growing startups. PMR’s collaborative environment is committed to building
industry-specific solutions by transforming data from multiple streams into a strategic
asset.
Contact Us:
Persistence Market Research
90 Sate Street, Suite 700 Albany, NY 12207
Tel: +1-518-618-1030
Email: [email protected]
Website: http://www.persistencemarketresearch.com/
[email protected]
Stay updated with our official Blog: http://pmrblog.com